Evolocumab in Patients at High Cardiovascular Risk Without P

Name: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Uploaded: 2025-11-11T05:00:00+00:00
Description: This video brief features Dr. Lawrence Leiter reporting from AHA 2025 in New Orleans. He presents primary results from the landmark VESALIUS-CV trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Clinical Perspective on New Therapies in Resistant Hypertension
Clinical Perspective on New Therapies in Resistant Hypertension
Cardiology
Clinical Perspective on New Therapies in Resistant Hypertension
- Clyde W. Yancy, MD
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits

Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial

Recommended

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 

Welcome to Global
Cardiology Academy